425mg/M2 I.V on day-1, 8 and 15 of radiotherapy course. (N = 24). On completion of CRT, evaluation done after 5 -11 weeks for feasibility of surgery. Results: In Group A 14/20 patients (70%) were selected for surgery. 11 patients (55%) underwent APR (abdomino perineal resection) and permanent colostomy. In 3 patients (15%) sphincter sparing Surgery was possible. None had positive surgical margin. None had developed grade 3 &/ or 4 acute toxicity after chemo-radiotherapy. At 12 months loco-regional relapse occurred in 8 patients (40%) and one had (5%) had multiple sites metastasis. At 24 months 16 patients were alive (80%) with local relapse in 8 (40%) and distant metastasis in 3 patients (15%). Group B: All patients underwent surgery. 19 patients underwent APR (67.8%) and permanent colostomy; 3 patients underwent sphincter preserving surgery (10.7%). 6 patients (21.4%) on laparotomy found unresectable due to pelvic adhesions. Bladder and rectal toxicity (92.8%) delayed surgery for 9 -13 weeks (median 11 weeks). 2 in the APR group and 1 in sphincter preserving surgery group showed pelvic recurrence at the end of 12 months and prolonged salvage chemotherapy was given. 2 patients (7.14%) developed distant metastasis. No evidence of disease till date (follow up for 27 months) was seen in 17 patients. Group C: Surgery was possible in 20 patients (83.3%). 4 patients discontinued treatment after CRT. All underwent APR. One patient (4.1%) had pelvic recurrence at 12 months and 1 at 24 months. Distant metastasis noted in 2 patients (8.2%). 5 patients had lower limb edema and swelling with no pelvic relapse. After chemo-radiotherapy acute rectal toxicity, grade 3 or 4 were (70.8%); grade 3/4 skin toxicity in 14 patients (58.3%); grade 3 diarrhoea in (37.5%). Conclusion: Hyperfractionated chemoradiotherapy is a better option for local control of advanced rectal adenocarcinoma although distal metastasis is same as conventional chemoradiotherapy.
